


PHARMACEUTICAL 2019

Verastem Inc. Rank 133 of 371







PHARMACEUTICAL 2019

Verastem Inc. Rank 133 of 371



The relative strengths and weaknesses of Verastem Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Verastem Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 84% points. The greatest weakness of Verastem Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 41% points.

The company's Economic Capital Ratio, given in the ranking table, is -73%, being 258% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	253,259
Cost of Goods Sold	165
Intangible Assets	21,577
Liabilities, Current	37,077
Liabilities, Non-Current	1,123
Other Assets	1,031
Other Compr. Net Income	129
Other Expenses	6,233
Other Liabilities	114,737
Other Net Income	2,603
Property and Equipment	1,369
Research and Development	43,648
Revenues	52,274
Selling, General and Administrative Expense	77,265

Output Variable	Value in 1000 USD
Assets	277,236
Liabilities	152,937
Expenses	127,311
Stockholders Equity	124,299
Net Income	-72,434
Comprehensive Net Income	-72,370
Economic Capital Ratio	-73%